Anticancer Activity of Vitamin D, Lumisterol and Selected Derivatives against Human Malignant Melanoma Cell Lines
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms252010914 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Paweł Domżalski und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Histology, Medical University of Gdansk, 1a Debinki, 80-211 Gdansk, Poland. Hauptthemen laut MEDLINE: Melanoma, Cell Proliferation, Antineoplastic Agents, Vitamin D. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Gdańsk.
Abstract (Originalsprache)
Despite the recent development of improved methods of treating melanoma such as targeted therapy, immunotherapy or combined treatment, the number of new cases worldwide is increasing. It is well known that active metabolites of vitamin D3 and lumisterol (L3) exert photoprotective and antiproliferative effects on the skin, while UV radiation is a major environmental risk factor for melanoma. Thus, many natural metabolites and synthetic analogs of steroidal and secosteroidal molecules have been tested on various cancer cells and in animal models. In this study, we tested the anti-melanoma properties of several natural derivatives of vitamin D3 and L3 in comparison to 1,25-dihydroxyvitamin D3 (1,25(OH)2D3). A significant decrease in melanoma cell proliferation and cell mobility was observed for selected derivatives, with (25R)-27-hydroxyL3 showing the highest potency (lowest IC50) in A375 cells but lower potency in SK-MEL-28 cells, whereas the parent L3 failed to inhibit proliferation. The efficacy (% inhibition) by 1,24,25(OH)3D3 and 1,25(OH)2D3 were similar in both cell types. 1,25(OH)2D3 showed higher potency than 1,24,25(OH)3D3 in SK-MEL-28 cells, but lower potency in A375 cells for the inhibition of proliferation. As for 1,25(OH)2D3, but not the other derivatives tested, treatment of melanoma cells with 1,24,25(OH)3D3 markedly increased the expression of CYP24A1, enhanced translocation of the vitamin D receptor (VDR) from the cytoplasm to the nucleus and also decreased the expression of the proliferation marker Ki67. The effects of the other compounds tested were weaker and occurred only under certain conditions. Our data indicate that 1,24,25(OH)3D3, which has undergone the first step in 1,25(OH)2D3 inactivation by being hydroxylated at C24, still shows anti-melanoma properties, displaying higher potency than 1,25(OH)2D3 in SK-MEL-28 cells. Furthermore, hydroxylation increases the potency of some of the lumisterol hydroxy-derivatives, as in contrast to L3, (25R)-27(OH)L3 effectively inhibits proliferation and migration of the human malignant melanoma cell line A375.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Histology, Medical University of Gdansk, 1a Debinki, 80-211 Gdansk, Poland.
- School of Molecular Sciences, University of Western Australia, Perth, WA 6009, Australia.
ORCID-Profile: Paweł Domżalski, Anna Piotrowska, Robert C Tuckey, Michał A Zmijewski
Förderung
- Medical University of Gdańsk
Zitieren
APA
Domżalski, P., Piotrowska, A., Tuckey, R. C., & Zmijewski, M. A. (2024). Anticancer Activity of Vitamin D, Lumisterol and Selected Derivatives against Human Malignant Melanoma Cell Lines. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252010914
Vancouver
Domżalski P, Piotrowska A, Tuckey RC, Zmijewski MA. Anticancer Activity of Vitamin D, Lumisterol and Selected Derivatives against Human Malignant Melanoma Cell Lines. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252010914
BibTeX
@article{Domalski2024,
author = {Domżalski, Paweł and Piotrowska, Anna and Tuckey, Robert C and Zmijewski, Michał A},
title = {Anticancer Activity of Vitamin D, Lumisterol and Selected Derivatives against Human Malignant Melanoma Cell Lines},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms252010914}
}
EUVIMED